Timolol Maleate Eye Drops

Pharmacological action: Timolol maleate is a non-selective beta;-adrenergic receptor blocker with no obvious endogenous sympathomimetic activity and local anesthetic effect, and no direct inhibitory effect on the myocardium. This product is timolol maleate eye drops, which can reduce intraocular pressure in patients with high intraocular pressure and normal people. The exact mechanism of its reduction of intraocular pressure is still unclear. Tonometry and aqueous humor fluorescence studies suggest that the intraocular pressure-lowering effect of this product is related to the reduction of aqueous humor production. Non-clinical toxicology study: Carcinogenicity: Animal experiments show that long-term and large-scale oral administration of timolol maleate can significantly increase the incidence of adrenal pheochromocytoma in male rats, benign and malignant lung tumors in female mice, benign uterine polyps and breast cancer. Reproductive toxicity: Animal experiments show that large doses of oral timolol maleate have no effect on the reproductive function of male and female mice.

Chemical name: (-)-1-(tert-butylamino)-3-[(4-morpholinyl-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate. Molecular formula: C13H24N4O3SC4H4O4. Molecular weight: 432.49.

Properties: This product is a colorless clear liquid.

It has a good effect of reducing intraocular pressure in primary open-angle glaucoma. For some secondary glaucoma, ocular hypertension, some primary angle-closure glaucoma and other glaucoma that are ineffective with other drugs and surgery, the addition of this product to the eye drops can further enhance the effect of reducing intraocular pressure.

Eye drops, 1 drop at a time, 1 to 2 times a day. If the intraocular pressure is under control, it can be changed to once a day. If other drugs are used, when switching to this product for treatment, the original drug should not be stopped suddenly. It should be gradually stopped from the second day of using this product.

1. The most common adverse reactions are burning and stinging of the eyes. 2. Cardiovascular system: bradycardia, arrhythmia. 3. Nervous system: dizziness, aggravation of myasthenia gravis symptoms, paresthesia, drowsiness, insomnia, nightmares, depression, mental confusion, hallucinations. 4. Respiratory system: bronchospasm, respiratory failure, dyspnea, nasal congestion, cough, upper respiratory tract infection. 5. Endocrine system: masking the symptoms of hypoglycemia in diabetic patients after taking insulin or hypoglycemic drugs.

1. Patients with bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease. 2. Sinus bradycardia, Ⅱ or Ⅲ degree atrioventricular block, obvious heart failure, cardiogenic shock. 3. Patients who are allergic to this product.

Precautions for children: This experiment has not been conducted and there are no reliable references. Precautions for pregnancy and lactation: The safety of this product for pregnant women has not been determined. This product can be detected in the breast milk of lactating women after eye drops. Because it has a variety of potential adverse reactions to breastfeeding infants, it is necessary to decide whether to stop breastfeeding or stop taking the drug based on the importance of the drops to the mother. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

1. Combined use with adrenaline may cause pupil dilation. 2. It is not recommended to use two local beta-receptor blockers at the same time. 3. This product should be used with caution in combination with calcium channel antagonists, as it may cause atrioventricular conduction block, left ventricular failure and hypotension. For patients with impaired cardiac function, the two drugs should be avoided in combination. 4. Patients who are taking catecholamine depleting drugs (such as reserpine) should be closely observed when using this product, as it may cause hypotension and significant bradycardia. 5. This product can further prolong atrioventricular conduction time when used in combination with digitalis and calcium channel antagonists. 6. This product can cause side effects of systemic beta-receptor blockade such as slow heart rate when used in combination with quinidine. The possible reason is that quinidine can inhibit the metabolism of timolol by P450 enzymes and CYPZD6.

Keep away from light and store in a sealed container.

8ml*40mg

24 months

Shandong Chenxin Fodu Pharmaceutical Co., Ltd.

• Founded in:

  2012-10-24

• Address:

  West side of the south end of Zhongdu Street, Wenshang County Economic Development Zone, Jining City, Shandong Province

• Tax NO.:

  91370830056218957G

• Registered Funds:

  108 million yuan

• Website:

  Log in to view

• Email:

  Log in to view